Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.32 USD | -0.39% | -7.81% | -32.78% |
Mar. 28 | Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target | MT |
Mar. 13 | Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.78% | 4.13B | |
-1.82% | 41.36B | |
+44.25% | 41.3B | |
+2.56% | 39.61B | |
-12.11% | 25.62B | |
+3.09% | 24.09B | |
-24.16% | 18.38B | |
+22.12% | 11.85B | |
-3.74% | 11.82B | |
+7.75% | 11.07B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Wells Fargo Upgrades Immunovant to Overweight From Equalweight, Boosts Price Target to $27 From $10